NDC product
Orilissa
NDC 0074-0038 · AbbVie Inc.
Key facts
| Product NDC | 0074-0038 |
|---|---|
| Proprietary name | Orilissa |
| Nonproprietary name | Elagolix |
| Substances | ELAGOLIX SODIUM |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | AbbVie Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA210450 |
| Pharmacologic classes | Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Jul 23, 2018 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: